Synonyms: GS-6207 | GS6207 | Sunlenca®
lenacapavir is an approved drug (EMA & FDA (2022))
Compound class:
Synthetic organic
Comment: Lenacapavir (GS-6207) is a novel long-acting anti-HIV lead that binds to the virus' at a conserved interface between capsid protein monomers [2]. This mechanism disrupts early and late phases of the viral replication cycle [1] [3]. PDB entry 6V2F shows the crystal structure of lenacapavir-bound HIV capsid hexamer.
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (EMA & FDA (2022)) |
International Nonproprietary Names | |
INN number | INN |
11108 | lenacapavir |
Synonyms |
GS-6207 | GS6207 | Sunlenca® |
Database Links | |
CAS Registry No. | 2189684-44-2 (source: WHO INN record) |
GtoPdb PubChem SID | 440816815 |
PubChem CID | 133082658 |
RCSB PDB Ligand | QNG |
Search Google for chemical match using the InChIKey | BRYXUCLEHAUSDY-WEWMWRJBSA-N |
Search Google for chemicals with the same backbone | BRYXUCLEHAUSDY |
Search PubMed clinical trials | lenacapavir |
Search PubMed titles | lenacapavir |
Search PubMed titles/abstracts | lenacapavir |
UniChem Compound Search for chemical match using the InChIKey | BRYXUCLEHAUSDY-WEWMWRJBSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | BRYXUCLEHAUSDY-WEWMWRJBSA-N |